越南肺炎链球菌疫苗市场评估:依疫苗类型,疫苗特性,给药途径,年龄层,最终用户,分销管道和地区划分的机会和预测（2017-2031）

越南肺炎链球菌疫苗市场规模将从2023年的1.1亿美元成长到2031年的1.8,829亿美元，预计2024-2031年期间复合年增长率为8.23%。

由于多种因素的影响，越南的肺炎球菌疫苗市场正在强劲增长，包括疫苗接种计划意识的提高、肺炎球菌疾病发病率的上升以及老年人口的增加，而老年人口特别容易受到严重感染。此外，政府和国际卫生组织在加强免疫计画和实施减轻肺炎球菌疾病负担的措施方面发挥积极作用，支持扩大越南肺炎球菌疫苗市场。

越南肺炎链球菌疫苗市场受到肺炎发病率上升的显着影响。肺炎主要影响易感人群，例如儿童、老年人和免疫系统较弱的人。由于盛行率不断上升，目前正积极进行宣传活动。此外，由于製药公司和研究机构为肺炎球菌疾病提供综合治疗的努力，越南的肺炎球菌疫苗市场显示出显着的进步和创造力。由于技术的发展和医疗保健基础设施支出的增加，肺炎球菌疫苗的可用性和可近性已显着改善。

此外，政府计划以及与全球卫生组织的合作伙伴关係正在显着影响越南肺炎球菌疫苗市场的成长。在积极的免疫计划和战术伙伴关係的推动下，疫苗接种率不断提高，大众对肺炎球菌疾病的认识不断提高。

肺炎盛行率高：

越南儿童肺炎盛行率位居前15名。这种呼吸道疾病是越南儿童医院住院的主要原因。在越南，导致 5 岁以下儿童罹患重症肺炎的危险因子有很多，包括营养不良、母乳哺育不足、免疫接种不足、出生体重过低、室内污染和居住条件过度拥挤。

技术进步推动市场：

技术进步是越南肺炎链球菌疫苗市场快速成长的原因。肺炎球菌疫苗接种最初是使用基于全细胞的技术开发的。其中包括为患者接种一种热灭活的 1 型血清细菌，这种细菌一直困扰着南非矿工。然而，MacLeod 等人的研究表明，用荚膜多醣进行免疫可以预防这种疾病，因此在疫苗製剂中使用了纯荚膜多醣。目前使用的肺炎链球菌疫苗是源自少数最常引起人类疾病的血清型的纯荚膜多醣。大多数许可机构目前批准两种类型的含有荚膜多醣的疫苗。一种是 PPSV，一种是 PCV。这些疫苗配方为越南肺炎链球菌疫苗市场的成长做出了重大贡献。

本报告调查了越南肺炎球菌疫苗市场，并提供了市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构、影响市场增长的因素分析以及案例研究。公司简介等

目录

第一章研究方法论

第二章 专案范围与定义

第 3 章执行摘要

第四章 越南肺炎链球菌疫苗市场前景

• 市场规模/预测
• 依疫苗类型
  • 减毒活疫苗
  • 灭活疫苗
  • 亚单位疫苗
  • 重组疫苗
• 依疫苗特性
  • 佐剂
  • 非佐剂
• 依给药途径
  • 肌肉内
  • 皮下
  • 皮内
  • 其他
• 依年龄
  • 婴儿
  • 孩子
  • 成人
• 依最终用户
  • 医院
  • 专科诊所
  • 居家护理
  • 其他
• 依分销渠道
  • 医院
  • 零售药店
  • 网上药店
  • 非政府组织
• 依地区
  • 北方
  • 南部
  • 中部
• 依公司划分的市场占有率

第 5 章 市场测绘

• 依疫苗类型
• 依疫苗特性
• 依给药途径
• 依年龄
• 依最终用户
• 依分销渠道
• 依地区

第六章 宏观环境与产业结构

• 供需分析
• 进出口分析
• 价值链分析
• PESTEL 分析
• 波特五力分析

第七章市场动态

• 生长促进因子
• 生长抑制因素（问题/限制）

第八章 监理框架与创新

• 临床试验
• 专利情况
• 监管审批
• 创新/新兴技术

第九节 主要公司状况

• 前 5 名市场领导者的竞争矩阵
• 前 5 名市场领导者的市场收入分析
• 併购/合资（如适用）
• SWOT分析（5家参与企业）
• 专利分析（如果适用）

第10章价格分析

第11章案例研究

第十二章 主要公司展望

• Pfizer Inc.
• Merck & Co., Inc.
• Walvax Biotechnology Co. Ltd.
• GlaxoSmithKline PLC.
• PnuVax Incorporated
• Novartis AG
• Serum Institute of Vietnam Pvt. Ltd.
• Panacea Biotec Limited
• Shenzhen Kangtai Biological Products Co., Ltd
• Sanofi Pasteur SA

第十三章 战略建议

第14章关于我们公司/免责声明

Vietnam pneumococcal vaccine market is projected to witness a CAGR of 8.23% during the forecast period 2024-2031, growing from USD 100.01 million in 2023 to USD 188.29 million in 2031. The Vietnam pneumococcal vaccine market is experiencing robust growth driven by multiple factors, such as an increased awareness of vaccination programs, a rise in pneumococcal disease incidences, and a growing elderly population that is particularly susceptible to severe infections. Additionally, governments and international health organizations are playing an active role in enhancing immunization programs and implementing initiatives to alleviate the burden of pneumococcal diseases, further bolstering the expansion of the Vietnam pneumococcal vaccine market.

The Vietnam pneumococcal vaccine market is significantly impacted by the rising incidence of pneumonia. Pneumonia primarily strikes susceptible populations, including children, the elderly, and those with weakened immune systems. There are now more awareness-raising campaigns because of the rise in instances. Moreover, due to the efforts of pharmaceutical companies and research organizations to provide comprehensive treatments against pneumococcal diseases, the Vietnam pneumococcal vaccine market has seen outstanding progress and creativity. Pneumococcal vaccination availability and accessibility have significantly improved because of technological developments and increased spending on healthcare infrastructure.

Additionally, government programs and alliances with global health organizations have had a big impact on the growth of the Vietnam pneumococcal vaccine market. As proactive immunization programs and tactical partnerships have gained traction, vaccine coverage has grown, and public awareness of pneumococcal illnesses has grown.

High Prevalence of Pneumonia

Vietnam ranks among the top 15 countries with the highest prevalence of child pneumonia. This respiratory condition is a major cause of hospital admissions in pediatric hospitals in Vietnam. Various risk factors contribute to severe pneumonia among children under the age of 5 in Vietnam, including malnutrition, inadequate breastfeeding practices, insufficient vaccinations, low birth weight, indoor pollution, and overcrowded living conditions. The impact of pneumonia on young children in Vietnam is well-documented; however, little is known about the prevalence of severe pneumonia and its risk factors in this age group. Therefore, the primary driver of the Vietnam pneumococcal vaccine market's expansion is the country's high rate of pneumonia cases.

Technological Advancements are Driving the Market

Technological advancements are responsible for the upsurge in the growth of the Vietnam pneumococcal vaccine market. Pneumococcal vaccinations were first developed utilizing whole-cell-based techniques. These entailed immunizing patients with heat-killed serotype 1 bacteria, which had afflicted South African miners. Nonetheless, studies by MacLeod et al. demonstrated that the sickness was prevented by immunization with capsular polysaccharides. Consequently, pure capsular polysaccharides were used in vaccine formulations. It is noteworthy that every pneumococcal serotype has biochemical and antigenic differences. It would be unfeasible to attain universal capsule-based immunization coverage against the hundreds of serotypes that are now in use. Rather, pure capsular polysaccharides from a small number of serotypes that cause human illness most frequently make up the pneumococcal vaccinations that are currently in use. Presently, most licensing agencies approve two types of vaccines containing capsular polysaccharides: one composed of 23 purified capsules (PPSV) and the other composed of 7, 10, or 13 purified capsules conjugated to a protein carrier (PCV). These vaccine formulations are significantly responsible for the growth of the Vietnam pneumococcal vaccine market.

The Demand for Pneumococcal Conjugate Vaccine is on the Rise

The extraordinary impact of the pneumococcal conjugate vaccination (PCV) is substantially responsible for the expansion of the Vietnam pneumococcal vaccine market. PCV is specially designed to boost the immune system's reaction to certain polysaccharides found on the bacteria's surface. These polysaccharides bind to carrier proteins through a process known as conjugation, which greatly improves the immune system's capacity to recognize and successfully fight the infection. Because of its novel architecture, PCV not only boosts immunity but also offers broader protection against a larger variety of pneumococcal serotypes. This transformative vaccine has emerged as a vital tool in reducing the burden of pneumococcal-related diseases and has played a pivotal role in safeguarding public health on a global scale. In 2021, a trial of pneumococcal vaccine schedules for PCV10 and PCV 13 was conducted in Ho Chi Minh City, Vietnam. The trial was sponsored by Murdoch Children's Research Institute, an Australian pediatric medical research institute located in Melbourne, Victoria.

Intramuscular Vaccines are in Great Demand

High demand for intramuscular vaccines is driving the Vietnam pneumococcal vaccine market. Intramuscular vaccinations are preferred due to their ability to elicit a strong immune response. Strong and long-lasting immune system activation is made possible by the muscle tissue's abundant blood supply and greater concentration of antigen-presenting cells. This ultimately results in a notable upsurge in the generation of protective antibodies and cultivates an improved immune memory, both of which are essential for sustained protection against pneumococcal infections. On the other hand, intradermal delivery entails injecting the vaccine into the skin's underlying layer. Although there is evidence to support the usefulness of this method in eliciting a robust and long-lasting immune response for pneumococcal immunization, it is not as well-supported as other vaccines.

Future Market Scenario (2024-2031F)

Vietnam pneumococcal vaccine market will also be influenced by the active role of healthcare organizations in enhancing immunization programs.

The increasing awareness regarding pneumonia disease will propel the growth of the Vietnam pneumococcal vaccine market in the future.

Several products by different companies are in the pipeline which are likely to be launched in coming years. Thus, the availability of new vaccine formulations will drive the growth of the Vietnam pneumococcal vaccine market.

The shift in population demographics toward the geriatric population will cause an increase in the overall number of people with diseases, such as Pneumonia, thereby propelling the market expansion.

Key Players Landscape and Outlook

Over the years, the Vietnam pneumococcal vaccine market has undergone significant changes, spurred by the urgent mission to combat pneumococcal diseases and safeguard public health. Recognizing the gravity of this health challenge, a multitude of pharmaceutical companies, research institutions, and governmental bodies have come to appreciate the importance of working together and consolidating their efforts. In May 2023, Pfizer (Vietnam) Limited Company and Vietnam Vaccine Joint Stock Company entered a memorandum of understanding (MoU) with the shared objective of comprehensive cooperation to safeguard public health, proactively combat diseases, and align with global advancements in healthcare, thereby positively impacting the well-being of the Vietnamese population. The primary focus of this joint project is to improve the proficiency of personnel in the development, implementation, and management of real-world data on vaccination, commonly known as "Real-World Evidence," in Vietnam. By doing so, the collaboration aims to gain valuable insights into vaccination patterns among the Vietnamese people, ensuring the safety and efficacy of vaccination practices.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Vietnam Pneumococcal Vaccine Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Type of Vaccine
  • 4.2.1. Live Attenuated Vaccines
  • 4.2.2. Inactivated Vaccines
  • 4.2.3. Subunit Vaccines
    • 4.2.3.1. Original Pathogen
    • 4.2.3.2. Polysaccharide Vaccine
    • 4.2.3.3. Conjugate Vaccine
    • 4.2.3.4. Protein-based Vaccine
  • 4.2.4. Recombinant Vaccine
• 4.3. By Vaccine Property
  • 4.3.1. Adjuvanted
  • 4.3.2. Non-adjuvanted
• 4.4. By Route of Administration
  • 4.4.1. Intramuscular
  • 4.4.2. Subcutaneous
  • 4.4.3. Intradermal
  • 4.4.4. Others
• 4.5. By Age group
  • 4.5.1. Infants
  • 4.5.2. Children
  • 4.5.3. Adults
• 4.6. By End-user
  • 4.6.1. Hospitals
  • 4.6.2. Specialty Clinics
  • 4.6.3. Homecare
  • 4.6.4. Others
• 4.7. By Distribution Channel
  • 4.7.1. Hospital
  • 4.7.2. Retail Pharmacy
  • 4.7.3. Online Pharmacy
  • 4.7.4. Non-Governmental Organizations
• 4.8. By Region
  • 4.8.1. Northern
  • 4.8.2. Southern
  • 4.8.3. Central
• 4.9. By Company Market Share (%), 2023

5. Market Mapping, 2023

• 5.1. By Type of Vaccine
• 5.2. By Vaccine Property
• 5.3. By Route of Administration
• 5.4. By Age group
• 5.5. By End-user
• 5.6. By Distribution channel
• 5.7. By Region

6. Macro Environment and Industry Structure

• 6.1. Supply Demand Analysis
• 6.2. Import Export Analysis
• 6.3. Value Chain Analysis
• 6.4. PESTEL Analysis
  • 6.4.1. Political Factors
  • 6.4.2. Economic System
  • 6.4.3. Social Implications
  • 6.4.4. Technological Advancements
  • 6.4.5. Environmental Impacts
  • 6.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 6.5. Porter's Five Forces Analysis
  • 6.5.1. Supplier Power
  • 6.5.2. Buyer Power
  • 6.5.3. Substitution Threat
  • 6.5.4. Threat from New Entrant
  • 6.5.5. Competitive Rivalry

7. Market Dynamics

• 7.1. Growth Drivers
• 7.2. Growth Inhibitors (Challenges and Restraints)

8. Regulatory Framework and Innovation

• 8.1. Clinical Trials
• 8.2. Patent Landscape
• 8.3. Regulatory Approvals
• 8.4. Innovations/Emerging Technologies

9. Key Players Landscape

• 9.1. Competition Matrix of Top Five Market Leaders
• 9.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 9.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 9.4. SWOT Analysis (For Five Market Players)
• 9.5. Patent Analysis (If Applicable)

10. Pricing Analysis

11. Case Studies

12. Key Players Outlook

• 12.1. Pfizer Inc.
  • 12.1.1. Company Details
  • 12.1.2. Key Management Personnel
  • 12.1.3. Products & Services
  • 12.1.4. Financials (As reported)
  • 12.1.5. Key Market Focus & Geographical Presence
  • 12.1.6. Recent Developments
• 12.2. Merck & Co., Inc.
• 12.3. Walvax Biotechnology Co. Ltd.
• 12.4. GlaxoSmithKline PLC.
• 12.5. PnuVax Incorporated
• 12.6. Novartis AG
• 12.7. Serum Institute of Vietnam Pvt. Ltd.
• 12.8. Panacea Biotec Limited
• 12.9. Shenzhen Kangtai Biological Products Co., Ltd
• 12.10. Sanofi Pasteur SA

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

13. Strategic Recommendations

14. About Us & Disclaimer

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Vietnam Pneumococcal Vaccine Market, By Value, In USD Million, 2017-2031F
• Figure 2. Vietnam Pneumococcal Vaccine Market, By Volume, In Thousand Units, 2017-2031F
• Figure 3. Vietnam Pneumococcal Vaccine Market Share (%), By Type of Vaccine, 2017-2031F
• Figure 4. Vietnam Pneumococcal Vaccine Market Share (%), By Vaccine Property, 2017-2031F
• Figure 5. Vietnam Pneumococcal Vaccine Market Share (%), By Route of Administration, 2017-2031F
• Figure 6. Vietnam Pneumococcal Vaccine Market Share (%), By Age Group, 2017-2031F
• Figure 7. Vietnam Pneumococcal Vaccine Market Share (%), By End-user, 2017-2031F
• Figure 8. Vietnam Pneumococcal Vaccine Market Share (%), By Distribution Channel, 2017-2031F
• Figure 9. Vietnam Pneumococcal Vaccine Market Share (%), By Region, 2017-2031F
• Figure 10. By Type of Vaccine Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 11. By Vaccine Property Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 12. By Route of Administration Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 13. By Age Group Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 14. By End-user Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 15. By Distribution Channel Map-Market Size (USD Million) & Growth Rate (%), 2023
• Figure 16. By Region Map-Market Size (USD Million) & Growth Rate (%), 2023